MedPath

Clinical Study of Yiqi Tongluo Prescription on Interventional Restenosis of Ischemic Cerebrovascular Disease

Phase 1
Recruiting
Conditions
Ischemic Cerebrovascular Disease
Registration Number
ITMCTR2000003899
Lead Sponsor
Dongfang Hospital of Beijing University of Chinese Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1. Patients with ischemic cerebrovascular disease were diagnosed by imaging examination;
2. Patients aged 35-80 years old;
3. Patients with endovascular interventional therapy;
4. Patients with Qi deficiency, blood stasis and phlegm obstruction were diagnosed by TCM syndrome score scale;
5. Patients with 0-2 scores of modified Rankin scale before onset of disease;
6. Patients who voluntarily participated in the study and have signed informed consent.

Exclusion Criteria

1. Patients who are expected to survive for less than 2 years;
2. Patients with severe systemic diseases or unsuitable / intolerant dual antiplatelet therapy;
3. Patients with severe neurological dysfunction (MRS score >= 3) before the stroke or TIA attack;
4. Patients with severe myocardial infarction within 2 weeks;
5. Patients with moyamoya disease, active arteritis and unexplained non atherosclerotic stenosis;
6. Patients with international normalized ratio (INR) > 1.5;
7. Pregnant women;
8. Patients who are not suitable for endovascular therapy as judged by neurologists and Neurointerventional physicians.
9. Patients with severe heart, liver and kidney damage;
10. Patients with a history of mental illness and mental retardation.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Degree of arterial stenosis;
Secondary Outcome Measures
NameTimeMethod
FABP4;Adverse events;NIHSS, mRS, BI;
© Copyright 2025. All Rights Reserved by MedPath